 Four years after launching Alivio Therapeutics, PureTech Health plc NASDAQ: PRTC is bringing the hydrogel player back into the fold by acquiring the remaining 22 stake of the company. Through the deal, PureTech will add Alivios programs for inflammatory diseases to its pipeline, including LYT-500, an oral treatment for inflammatory bowel disease IBD. 